Agentix (AGTX) Stock Price

Agentix Price

OTC·CLOSED
0.02
​
Market closed

Revenue at Agentix has contracted by 36.6% per year over the past 7 years to 1,240.00 USD. For Agentix, the net margin of -108,092.5% is down versus -617.2% a few years ago.

Agentix stock price

Access this data via the Eulerpool API

Agentix business model & stock analysis

Agentix Corp.is a biotechnology company, which engages in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease and ischemic reperfusion injury. The company is headquartered in Dana Point, California. The company went IPO on 2015-08-05. The firm is engaged in developing therapeutic agents for the treatment of metabolic diseases like Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its pipeline includes AGTX-2004 and AGTX-2003. AGTX-2004 is a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM). AGTX-2003 is a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease. The firm is focused on the development of synthetic agonists, inverse agonists, and antagonists, which modulate the endocannabinoid system (ECS). The ECS is the regulatory system which governs metabolism. The Company’s wholly owned subsidiaries include GSL Healthcare, Inc., Agentix Australia Pty Ltd, and Applied Biopharma LLC.

Frequently asked questions about Agentix

Converted at the current exchange rate, the Agentix share trades at 0.02 EUR (0.02 USD).

The revenue cannot currently be calculated for Agentix.

The profit of Agentix is -485,636.00 USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Agentix is currently -1.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Agentix stock.

The P/S cannot be calculated for Agentix currently.

The Eulerpool Quality Score for Agentix is 2/10.

The ISIN of Agentix is US00848A1034. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Agentix is AGTX. The ticker symbol is used to trade Agentix shares on the stock exchange.

Fair ValueTerminal
0.02 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Aug 5, 2015
ISIN
US00848A1034
Cusip
00848A103
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
3.59
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
14.98 %
Last updated Oct 9, 2026, 8:26 AM

Agentix Peer Group

Agentix Ticker

OTC · AGTXOTC · AGTX

Agentix FIGI

AGTX:US · BBG0068Q8V76AGTX:PQ · BBG0068Q8VP6AGTX:UV · BBG0068Q8VR4

All fundamentals and in-depth analysis of Agentix

Our stock analysis for Agentix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agentix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.